TransMedics Group, Inc. (TMDX) financial statements and ratios from SEC XBRL: revenue $605.49M (TTM), net margin 31.4%, revenue growth 37.1% YoY, P/E 58.5. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $605.49M |
| Net Margin | 31.4% |
| Revenue Growth (YoY) | 37.1% |
| EPS Growth (YoY) | 423.4% |
| FCF Growth (YoY) | -265.0% |
| P/E Ratio | 58.5 |
| EV / EBITDA | 19.2 |
| Price / Book | 6.06 |
| Price / Sales | 4.61 |
| FCF Yield | 2.8% |
| DCF Value (model) | $174.34 |
| DCF Upside vs Price | 91.9% |
| Altman Z-Score | 4.29 (safe) |
| Sector P/E (Healthcare) | 21.6 |
TMDX overview · TMDX earnings · TMDX KPIs · TMDX investor relations · TMDX ownership · TMDX peers · TMDX filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.